Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 1996

View Archived Issues

Silkis licensed to Galderma

Azelex now available to treat acne

ALA-PDT to be studied for hair removal

L-742728 selected by Merck & Co. for further evaluation

Mentax approvable for athlete's foot

New antifungals isolated from actinomycetes at Schering-Plough

AmBisome approved for marketing in Spain

Dutch approval for Amphocil

S-28679, a new interferon biosynthesis inducer from 3M

Anti-HSV compound karalicin

New patent issued to Interferon Sciences

Expanded access for delavirdine initiated

DaunoXome approved as first-line treatment for KS

Cell Genesys to evaluate new gene therapy for AIDS

Virulizin clinical trials reinitiated for KS

COX-2 inhibitor research continues at Merck Frosst

Amiprilose advances to phase III in rheumatoid arthritis

Corixa in-licenses Optivax delivery system for vaccines

Gastrimmune phase I/II trial completed

BR96 produced successfully in milk from transgenic goats

Virulizin clinical trials resume in pancreatic cancer

Isis, Ciba-Geigy evaluate antisense drug in phase I

Banyu discovers new thioredoxin system inhibitor

Thalidomide in phase II at NCI for cancer indications

Banyu reports synthesis and activity of BE-39907A2

Immune Response in-licenses gene therapy for brain tumors

NT-3 lessens cisplatin toxicity in rats

New alpha2-adrenoceptor agonist reported by Allergan

Conjugated estrogens + pravastatin effective in treating hypercholesterolemia in women

Gene for Werner's syndrome discovered

Shanghai Institute will scale up SunPharm's deferoxamine

Patient enrollment completed for FS069 trial

Nuclear matrix proteins for detection of bladder cancer

TruQuant BR approved in U.S.

Dusa's ALA for detection of bladder cancer

Sero-Strip HIV-1/2 efficacy demonstrated at CDC

Hema-Strip HIV-1/2 approved in Singapore

Abbott has option to license TB diagnostic from Inflazyme

PP-14 gives positive interim clinical results

AltaRex, Resolution to codevelop cancer diagnostics

Amersham reaches licensing agreement for Ceretec

Atypical antipsychotics from Spanish university

Genetic markers for manic depression discovered

Organogenesis to develop treatments based on oral mucosa

Sequana, Aurora establish drug discovery collaboration

Pharmacopeia will collaborate with Daiichi for drug discovery

RMP-7 phase II trials initiated

Isopharma established to develop radioactive healthcare products

Fujisawa acquires equity interest in PharMingen

Paracelsian option to acquire East West Herbs

Genentech to develop neurturin for neurodegenerative disorders

Carbonic anhydrase inhibitor tested for parkinsonism

Neruocrine Biosciences, Ciba-Geigy ally for MS research

T cell receptor vaccine effective in MS

ABT-089 candidate drug for Alzheimer's disease

Senju reports tocopherol derivatives

COX-2 inhibitor reported by Searle

Neuronal cell protectant isolated from natural source

Hu23F2G advances to phase II

Lubeluzole + DCLHb potentially effective in stroke

BDNF, CNTF protect against metabolic stress in vitro

New antiasthma drugs from the SmithKline Beecham Laboratory

Zafirlukast approval recommended

Sanofi Winthrop claims elastase inhibitors

New angiotensin II antagonists from Kotobuki

YM-087 in phase I for CHF

Neutralase to enter phase II

ATIII in development at Genzyme Transgenics

Fibrinogen antagonists from Yamanouchi

Merck & Co. describes fibrinogen antagonists

XR-300 fibrinogen antagonist in preclinical testing

Novel prostaglandin D2 agonists from Glaxo Wellcome

OraVax granted patent on H. pylori vaccine technology

Nisin in testing for Helicobacter infections

Improved Havrix approved by FDA

Vaqta gets the green light from FDA

Sertoli Technologies formed to develop new technology

New thiazolidinedione, MCC-555, reported by Mitsubishi Chemical

Anergen, Novo Nordisk expand diabetes collaboration

Selective protein kinase C beta antagonist discovered by Lilly

NT-3 shows potential in diabetic neuropathy

Fujisawa in-licenses zenarestat

Testosterone transdermal patch approved in Sweden

Vivus files NDA for Muse

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...